RxDoctor Payments Data

Ian Hotchkiss, DO

Family Medicine · Nampa, IDNPI 1174063036

Payments from drug & device makers

$1,005in general payments, 2019–2025

Across 22 payments — averaging $45.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$234
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$134
  • Regeneron Healthcare Solutions, Inc.$122
  • Pfizer$121
  • Teva Pharmaceuticals USA, Inc.$120
  • AbbVie$119
  • plus $153 from 4 others

What the payments were for

  • Food & beverage$1,005100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,005 in reported general payments places this provider in the 70th percentile of 803 family medicine providers in Idaho.

See all family medicine providers in Idaho

Medicare billing

Part B allowed, 2024
$45,274
Medicare patients
186
Services billed
428

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban124$122,441
OzempicSemaglutide67$84,567
Trelegy ElliptaFluticasone/Umeclidin/Vilanter55$42,837
XifaxanRifaximin12$38,479
FarxigaDapagliflozin Propanediol34$33,236
TrulicityDulaglutide24$27,239
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog19$25,947
JanuviaSitagliptin Phosphate21$25,636
MyrbetriqMirabegron35$25,362
XareltoRivaroxaban14$19,650
MounjaroTirzepatide15$17,026
Breo ElliptaFluticasone/Vilanterol21$9,828
Combivent RespimatIpratropium/Albuterol Sulfate19$8,759
Atorvastatin Calcium624$5,272
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$4,412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$121$122,441124 claims
AstraZenecaFarxiga$77$33,23634 claims
MerckJanuvia$48$25,63621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 803 family medicine providers in Idaho.

Other family medicine in Nampa

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →